Tag Archives: Benzodiazepines

Clinical Anxiety as a Dementia Risk Factor? (BMJ Open)

Posted on May 9, 2018 by Dementia and Elderly Care News

Summary There are some indications that anxiety in midlife is associated with an increased risk of dementia, even after allowing for any anxiety which might have been expected to arise as a result of prodromal cognitive decline / pre-clinical dementia. … Continue reading →

Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Mental Health, Quick Insights, Statistics, Systematic Reviews, UK, Universal Interest | Tagged Anxiety, Anxiety Disorders, Anxiety Disorders and Dementia, Anxiety: Potential Dementia Risk Factor, Benzodiazepines, Benzodiazepines and Dementia, BMJ Open, BMJ Publishing Group Ltd, Clinical Anxiety: Possible Dementia Risk Factor, Dementia Risk Factors, Diseases and Medical Conditions Associated With Increased Risk of Mild Cognitive Impairment (MCI), Division of Psychiatry: University College London, Faculty of Medicine: University of Southampton, MCI: Mild Cognitive Impairment, Midlife Anxiety, Mild Cognitive Impairment (MCI), Newcastle-Ottawa Scale, Overlapping Risk Factors, Personality (Risk Factor), Psychosocial Protective and Risk Factors, Risk Factors, Risk Factors for Alzheimer's Diseease, Systematic Review, University College London, University of Southampton | Leave a comment

Our Invisible Addicts: Updated Edition (Royal College of Psychiatrists / BBC News / ONS / Wiley)

Posted on March 9, 2018 by Dementia and Elderly Care News

Summary The Royal College of Psychiatrists has published a second edition of the “Our Invisible Addicts” report, which presents updates to evidence concerning mental health aspects of alcohol and substance misuse in the “baby boomer” generation. It advises that substance … Continue reading →

Reducing Antipsychotic Prescribing for BPSD (BMJ / JAMA / JAMA Psychiatry / BJCP)

Posted on November 6, 2014 by Dementia and Elderly Care News

Summary This BMJ “Change page” article discusses the potential harms associated with use of antipsychotics in people with dementia, and covers guidelines recommending restrictions in their use. Risperidone is the antipsychotic recommended for use in the treatment of aggression associated … Continue reading →

Posted in Acute Hospitals, Antipsychotics, Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Person-Centred Care, Pharmacological Treatments, Practical Advice, Quick Insights, Standards, Statistics, UK | Tagged Adverse Drug Reactions (ADRs), Adverse Drug Reactions (ADRs): Type A (Potentially Avoidable and Associated With Commonly Prescribed Medications), Adverse Drug Reactions in the Elderly, Adverse Effects, Aggression, Aggressive Behaviour, Alternatives to Antipsychotics, Antidepressants, Antihypertensives, Antipsychotic Drugs, Antipsychotics, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics Limitation in Dementia, Antipsychotics Side Effects, Antipsychotics-Related Mortality Risks, Antipsychotics: Absolute Mortality Risk Increase, Antipsychotics: Neuroleptic Sensitivity, Antipsychotics: Number Needed to Harm (NNH), Atypical Antipsychotics, Behavioural and Psychological Symptoms of Dementia (BPSD), Benzodiazepines, BMJ, BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, Brief Psychosocial Treatment, British Journal of Clinical Pharmacology, British Medical Journal (BMJ), Campbell Institute (CAMH): University of Toronto, Cardiff University, Center for Clinical Management Research: Veterans Affairs Ann Arbor Healthcare System (Michigan), Center for Statistical Consultation and Research: University of Michigan, CitAD Research Group, Citalopram for Agitation in Alzheimer's Disease: CitAD Trial, Clinical Biotechnology Research Institute: Roper St Francis Healthcare (Charleston: South Carolina), College of Physicians and Surgeons of Columbia University, DART-AD: Dementia Antipsychotic Withdrawal Trial (DART-AD), Dementia Antipsychotic Withdrawal Trial (DART-AD), Department of Psychiatry: University of Michigan, Department of Psychiatry: University of Southern California, Discontinuation of Antipsychotics, Effect of Citalopram on Agitation in Alzheimer Disease (CitAD Randomized Clinical Trial), Falls Prevention, Hotchkiss Brain Institute: University of Calgary, Inappropriate Prescribing, Inappropriate Use of Antipsychotics in Dementia, International Conference on Harmonization, JAMA, JAMA Psychiatry, Johns Hopkins Bayview and Johns Hopkins School of Medicine, Johns Hopkins Bloomberg School of Public Health: Baltimore, Kings College London, Medication Reviews, National Institute for Health Research (NIHR): Mental Health Biomedical Research Centre and Dementia Unit, NEST Approach, Neuroleptic Discontinuation, Neuroleptics, New York State Psychiatric Institute, Patients’ Needs and the Environment Stimulation and Techniques (NEST), Perelman School of Medicine: University of Pennsylvania, Personalised Social Interaction, Pharmacokinetics, Polypharmacy, Potential Harms of Antipsychotic Use, Prescribing Anti-Psychotic Drugs to People with Dementia, Reducing Agitation and Distress, Reducing Antipsychotic Medication in Care Homes, Reducing Antipsychotic Prescriptions in Dementia, Reducing Inappropriate Use of Antipsychotics in Dementia, Reducing Violence and Aggression, Risperidone, Seattle Protocols, Simulated Presence Therapy, South London and Maudsley NHS Foundation Trust, Stanford University School of Medicine, United States, University Hospital Llandough (Cardiff), University of Calgary, University of Manchester, University of Michigan, University of Pennsylvania, University of Rochester School of Medicine and Dentistry, University of Southern California, University of Southern California Keck School of Medicine, University of Toronto, Violence and Aggression, Wolfson Centre for Age-Related Diseases: King’s College London | Leave a comment

Dementia Revealed: Dementia Guide / Toolkit for GPs (NHS England / Department of Health / RCGP)

Posted on September 17, 2014 by Dementia and Elderly Care News

Summary NHS England has a commitment to improve dementia diagnosis rates. NHS England has published a guide to help GPs perform better on the timely diagnosis of dementia and to offer advice on post-diagnostic support for the person with the … Continue reading →

Posted in Alzheimer's Society, Antipsychotics, Charitable Bodies, Commissioning, Community Care, Delirium, Department of Health, Diagnosis, End of Life Care, Falls, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), Integrated Care, Management of Condition, Mental Health, Models of Dementia Care, National, NHS, NHS England, Non-Pharmacological Treatments, Patient Care Pathway, Person-Centred Care, Pharmacological Treatments, Practical Advice, Quick Insights, Standards, UK, Universal Interest | Tagged 4AT Score, 4AT Screening Instrument for Rapid Initial Assessment of Delirium and Cognitive Impairment, Abbreviated Mental Test Score (AMTS), ACE III: Modified Addenbrooke’s Test, Activities of Daily Living (ADLs), Acute Change or Fluctuating Course, Addenbrooke's Cognitive Examination (ACE), Advance Decision to Refuse Treatment (ADRT), Advance Directives, Agitation, Alcohol Consumption, Alcohol Misuse, Alistair Burns: NHS England’s National Clinical Director for Dementia, Alternatives to Medication for Agitation, AMT4 (Abbreviated Mental Test - 4), Anticholinergic Drugs, Anticholinergics, Antipsychotics Limitation in Dementia, Antipsychotics: Neuroleptic Sensitivity, AT4 (Delirium Scale), Behavioural and Psychological Symptoms of Dementia (BPSD), Benefits Advice, Benzodiazepines, BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, Care Homes, Caregiver Assessments, Carers' Assessments, Clomethiazole, Coding of Dementia, Cognitive Stimulation Therapy (CST), Dementia and Alcohol, Dementia and Driving Guidance, Dementia Coding, Dementia Diagnosis Rates, Dementia Prevalence Calculator, Dementia Revealed: Dementia Guide for GPs, Dementia Toolkit for GP Commissioners, Dementia Toolkit for GPs, Deprivation of Liberty Safeguards (DoLS), Diagnosis and Assessment, Diagnosis and Referral, Diagnosis and Support, Diagnosis at Primary Care Level, Dr Elizabeth Barrett: Shires Health Care (Hardwick CCG), Driving, Driving and Dementia, Early Diagnosis, Fluctuation Assessment Scales, Fluctuations, General Practice, General Practice in England, General Practices, General Practitioner Assessment of Cognition (GPCOG), Geriatric Depression Scale, GPCog (The General Practitioner assessment of Cognition), GPs' Dementia Toolkit, IMCAs and Safeguarding, Improving Coding, Improving Dementia Diagnosis Rates, Improving General Practice, Inappropriate Use of Antipsychotics in Dementia, Independent Mental Capacity Advocates (IMCAs), Lasting Power of Attorney (LPoA), Lorazepam, Low Dose Antipsychotics, Managing Agitation, Memantine, Memory Clinics, Mini Mental State Examination (MMSE), Mirtazapine, Montreal Cognition Assessment (MOCA), NHS Continuing Care, NHS Hardwick CCG, Post-Diagnosis Support, Post-Diagnostic Support, Primary Care, Professor Alistair Burns, Quetiapine, RCGP, Risperidone, Rivastigmine, Royal College of General Practitioners (RCGP), Safeguarding Vulnerable Adults, Sertraline, Shires Health Care, Simon Stevens: Chief Executive of NHS England (2014-), Social Services, Support for Improving Dementia Diagnosis Rates, Temazepam, Timely Diagnosis, Trazodone, Voluntary Organisations, Wernicke-Korsakoff Syndrome, Zopiclone | Leave a comment

Use of Benzodiazepines and Increased Risk of Alzheimer’s Disease (BBC News / BMJ)

Posted on September 12, 2014 by Dementia and Elderly Care News

Summary Long-term use of benzodiazepines, often prescribed for anxiety and sleep problems, appears to be linked to an increased risk of developing Alzheimer’s Disease. A French-Canadian team of researchers have found a cumulative dose-effect association between exposure to benzodiazepines (over … Continue reading →

Posted in Acute Hospitals, BBC News, Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Mental Health, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, Statistics, Universal Interest | Tagged Anxiety, Behind the Headlines, Benzodiazepine Use and Risk of Alzheimer's Disease, Benzodiazepines, BMJ, British Medical Journal (BMJ), Canada Faculty of Pharmacy: University of Montreal, Dose-Response Effect, Epidemiology, French Institute of Public Health Research (IRESP), French Ministry of Health (Direction Générale de la Santé), French National Institute of Health and Medical Research (INSERM), Funding Agency for Health Research of Quebec (Fonds de la Recherche en Santé du Québec) (FRSQ), INSERM, Inserm Research Center for Epidemiology and Biostatistics: Bordeaux, Insomnia, Institute of Health and Medical Research (Inserm), IRESP (Institut de Recherche en Santé Publique), Pharmacoepidemiology, Prescription Sleeping Pills, Quebec Health Insurance Program Database (RAMQ), Research Center of the University of Montreal Hospital Center (CRCHUM), Risk Factors, Risk Factors for Alzheimer's Diseease, Sedatives, Sleeping Pills, Sleeping Problems, Université de Bordeaux, University of Bordeaux: College of Health Sciences, University of Montreal, University of Montreal Hospital Center | Leave a comment

Renewed Call for Parity of Esteem for Mental and Physical Health (BBC News / Department of Health)

Posted on September 9, 2014 by Dementia and Elderly Care News

Summary Professor Dame Sally Davies, England’s Chief Medical Officer, has expressed support for giving mental health services a higher priority, with targets for waiting times and better protection for funding. Mental illness is estimated to cost between £70bn and £100bn … Continue reading →

Pharmacological Treatments for Neuropsychiatric Symptoms in Alzheimer’s Disease (Journal of Neurology Neurosurgery and Psychiatry)

Posted on June 25, 2014 by Dementia and Elderly Care News

Summary This systematic review investigates the efficacy and safety of various pharmacological treatments for neuropsychiatric symptoms in Alzheimer’s Disease patients. It concludes that cholinesterase inhibitors (ChEIs) and atypical antipsychotics could improve neuropsychiatric symptoms in these patients, but with poor patient … Continue reading →

Posted in Antipsychotics, Depression, For Doctors (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Models of Dementia Care, Pharmacological Treatments, Systematic Reviews | Tagged Adverse Drug Reactions, Adverse Effects, Adverse Events, Antidepressants, Antipsychotics and Risk of Venous Thromboembolism, Antipsychotics Limitation in Dementia, Antipsychotics Side Effects, Antipsychotics-Related Mortality Risks, Antipsychotics: Neuroleptic Sensitivity, Atypical Antipsychotics, Behavioural and Psychological Symptoms of Dementia (BPSD), Benzodiazepines, Benzodiazepines for BPSD, BPSD, BPSD: Behavioral and Psychological Symptoms of Dementia, Cerebrovascular Adverse Events, ChEIs: Cholinesterase Inhibitors, China, Cholinesterase Inhibitors, Journal of Neurology Neurosurgery and Psychiatry, Memantine, Mood Stabilisers, Nanjing Medical University, Neuropsychiatric Inventory (NPI), Neuropsychiatric Symptoms in Alzheimer’s Disease, Patient Safety, Pharmacological Treatments for Neuropsychiatric Symptoms in Alzheimer’s Disease, Qingdao Municipal Hospital, Qingdao University, Serious Adverse Events, Shandong Province, Systematic Reviews and Meta-Analyses | Leave a comment

Tag Archives: Benzodiazepines

Clinical Anxiety as a Dementia Risk Factor? (BMJ Open)

Use of Benzodiazepines and Increased Risk of Alzheimer’s Disease (BBC News / BMJ)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites